vonoprazan

Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis

Vonoprazan fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase.

Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.

Vonoprazan-d4 is a deuterated compound of Vonoprazan. Vonoprazan has a CAS number of 881681-00-1. Vonoprazan is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis

Vonoprazan-d3 is a deuterated compound of Vonoprazan. Vonoprazan has a CAS number of 881681-00-1. Vonoprazan is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis

Vonoprazan-d4 Fumarate is a deuterated compound of Vonoprazan Fumarate.

Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively acts as a potassium-competitive acid blocker (P-CAB) with potent antisecretory activity. It notably inhibits H+,K+-ATPase activity in porcine gastric microsomes, demonstrating an IC50 of 19 nM at pH 6.5. Primarily developed for researching acid-related diseases like gastroesophageal reflux disease and peptic ulcer disease, vonoprazan hydrochloride also serves in the eradication of Helicobacter pylori [1] [2] [3].